Biofrontera Inc Overview
Industry: Drug Manufacturers Specialty & Generic
Sector: Healthcare
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription drug for the treatment of impetigo. The company was founded in 1997 and is headquartered in Woburn, Massachusetts.
Biofrontera Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Biofrontera Inc in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Biofrontera Inc Competitors
Biofrontera Inc operates in the Drug Manufacturers Specialty & Generic industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans